Search This Blog

Tuesday, March 10, 2026

Tenax Phase 3 LEVEL trial hits 230-patient target with Q3 2026 topline data expected

 

Tenax Therapeutics Q4 2025 results beat EPS and revenue estimates as Phase 3 LEVEL trial hits 230-patient target with Q3 2026 topline data expected

  • Fiscal Q4 2025 non-GAAP EPS was $-0.38, down 111% year over year, beating EPS estimates.
  • Fiscal Q4 2025 revenue was $0 while still beating revenue estimates.
  • Company projects existing cash resources will fund operations through 2027 following Q4 and full-year 2025 results.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)